Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia
- 11 April 2019
- journal article
- research article
- Published by Springer Nature in Obesity Surgery
- Vol. 29 (7) , 2092-2099
Abstract
Background Hypoglycemia is an increasingly recognized complication of bariatric surgery. Mechanisms contributing to glucose lowering remain incompletely understood. We aimed to identify differentially abundant plasma proteins in patients with post-bariatric hypoglycemia (PBH) after Roux-en-Y gastric bypass (RYGB), compared to asymptomatic post-RYGB. Methods Proteomic analysis of blood samples collected after overnight fast and mixed meal challenge in individuals with PBH, asymptomatic RYGB, severe obesity, or overweight recruited from outpatient hypoglycemia or bariatric clinics. Results The top-ranking differentially abundant protein at 120 min after mixed meal was fibroblast growth factor 19 (FGF-19), an intestinally derived hormone regulated by bile acid-FXR signaling; levels were 2.4-fold higher in PBH vs. asymptomatic post-RYGB (mean + SEM, 1094 ± 141 vs. 428 ± 45, P < 0.001, FDR < 0.01). FGF-19 ELISA confirmed 3.5-fold higher concentrations in PBH versus asymptomatic (360 ± 70 vs. 103 ± 18, P = 0.025). To explore potential links between increased FGF-19 and GLP-1, residual samples from other human studies in which GLP-1 was modulated were assayed. FGF-19 levels did not change in response to infusion of GLP-1 and PYY in overweight/obese individuals. Infusion of the GLP-1 receptor antagonist exendin 9–39 in recently operated asymptomatic post-RYGB did not alter FGF-19 levels after mixed meal. By contrast, GLP-1 receptor antagonist infusion yielded a significant increase in FGF-19 levels after oral glucose in individuals with PBH. While plasma bile acids did not differ between PBH and asymptomatic post-RYGB, these data suggest unique interrelationships between GLP-1 and FGF-19 in PBH. Conclusions Taken together, these data support FGF-19 as a potential contributor to insulin-independent pathways driving postprandial hypoglycemia in PBH.Keywords
Funding Information
- MedImmune (xxxx)
- Somalogic (xxx)
- American Society of Metabolic and Bariatric Surgery (xxxx)
This publication has 41 references indexed in Scilit:
- Beta‐cell sensitivity to glucose is impaired after gastric bypass surgeryDiabetes, Obesity and Metabolism, 2017
- Weight and Metabolic Outcomes 12 Years after Gastric BypassNew England Journal of Medicine, 2017
- Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year OutcomesNew England Journal of Medicine, 2017
- Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemiaDiabetologia, 2016
- How common is hypoglycemia after gastric bypass?Obesity, 2016
- The rollercoaster of post-bariatric hypoglycaemiaThe Lancet Diabetes & Endocrinology, 2016
- Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trialThe Lancet, 2015
- Roux-en-Y Gastric Bypass Surgery or Lifestyle With Intensive Medical Management in Patients With Type 2 DiabetesJAMA Surgery, 2014
- Altered Islet Function and Insulin Clearance Cause Hyperinsulinemia in Gastric Bypass Patients With Symptoms of Postprandial HypoglycemiaThe Journal of Clinical Endocrinology & Metabolism, 2014
- Patients with Neuroglycopenia after Gastric Bypass Surgery Have Exaggerated Incretin and Insulin Secretory Responses to a Mixed MealThe Journal of Clinical Endocrinology & Metabolism, 2007